test Browse by Author Names Browse by Titles of Works Browse by Subjects of Works Browse by Issue Dates of Works
       

Advanced Search
Home   
 
Browse   
Communities
& Collections
  
Issue Date   
Author   
Title   
Subject   
 
Sign on to:   
Receive email
updates
  
My Account
authorized users
  
Edit Profile   
 
Help   
About T-Space   

T-Space at The University of Toronto Libraries >
University of Toronto at Scarborough >
Bioline International Legacy Collection >
Bioline International Legacy Collection >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1807/9248

Title: 1H Magnetic Resonance Spectroscopy Assessment of the Effects of Rivastigmine on Patients with moderate Alzheimer Disease
Authors: Arturo, Alvarado
Yelena, Figueroa
Alberto, Mendoza
Hodalitz, Ortíz
Valentina, Itriago
Mariangela, Alvarado
Keywords: 1H Magnetic Resonance Spectroscopy (MRS), Alzheimer's Disease (AD), Mini Mental State Examination (MMSE), Rivastigmine
Issue Date: 31-Dec-2005
Publisher: Centro de Análisis de Imágenes Biomédicas Computarizadas-CAIBC0
Citation: VITAE Academia Biomédica Digital (ISSN: 1317-987x) Num 24
Abstract: This study was designed to perform MRS of the Temporal Lobe (TL) and Frontal Lobe (FL) to assess brain metabolic changes that result from treating moderate-AD (AD) patients with Rivastigmine. Twenty AD patients were studied after obtaining both their informed consent and their caregivers'. They were divided into two groups of ten patients each one: Rivastigmine Group (RG) and Control Group (CG), and matched by age and sex. RG took Rivastigmine during 16 weeks (1.5 mg/day the first two weeks, 3 mg/day the following six weeks, and 4.5 mg/day the last eight weeks). CG took placebo during 16 weeks. Mini-Mental State Examination (MMSE), Magnetic Resonance Imaging (MRI), and MRS were performed before and after the 16-week study. MRI and MRS were carried out on a 1.5 Tesla system (Sonata, Siemens Erlangen®). Single Voxel Spectroscopy (1.8 cm x 1.8 cm x 1.8 cm = 5.83 cm3) were acquired with a 90°-180°-180° Spin-Echo Sequence (TR=1500 msec, TE=30 msec,192 averaged acquisitions). N-Acetylaspartate (NAA), Creatine (Cr), Choline (Cho), and myo-inositol (mI) intensity signals were detected and NAA/Cr, mI/Cr, Cho/Cr and NAA/mI ratios were calculated. Analysis of Variance was applied to the results. Tukey test was used for comparisons among ratio means with Bonferroni correction for small samples. Spearman rank correlation coefficients were calculated for both MMSE scores and measured metabolite ratios. A significant increase (p<0.05) in the NAA/Cr ratio for the Right FL and a significant increase (p<0.05) in the NAA/mI ratio for the Left TL were found in the RG after 16 weeks of Rivastigmine treatment. These changes were correlated to the RG patients' improvement in cognitive mental status that was uncovered through the MMSE's AD Assessment Scale Scores. No significant changes were found in the CG after 16 weeks of placebo treatment. MRS may provide a useful tool for monitoring the therapeutic response of AD patients to Rivastigmine. The link between MRS-based Rivastigmine monitoring and the MMSE's AD Assessment Scale Scores may also provide a fertile ground for developing a Rivastigmine-based therapy and predicting its efficacy to improve AD patients' cognitive status.
URI: http://hdl.handle.net/1807/9248
Other Identifiers: http://www.bioline.org.br/abstract?id=va05011
Rights: Copyright 2005 - Centro de Análisis de Imágenes Biomédicas Computarizadas CAIBCO, Instituto de Medicina Tropical - Facultad de Medicina, Universidad Central de Venezuela
Appears in Collections:Bioline International Legacy Collection

Files in This Item:

File Description SizeFormat
va05011.pdf561.11 kBAdobe PDF
View/Open

Items in T-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

uoft